Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17545537,MTD,"The doses tested ranged from 1.3 to 26.1 microg/kg, and the MTD was defined as 10.4 microg/kg based on toxicities similar to those of aldesleukin.","Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545537/),[Î¼g] / [kg],10.4,97443,DB00041,Aldesleukin
,17545537,half-life,Pharmacokinetics showed dose-dependent peak concentrations (C(max)) and area under the curve with a half-life of approximately 2 h and no evidence of accumulation.,"Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545537/),h,2,97444,DB00041,Aldesleukin
,9363872,overall response rate,"Among 35 assessable patients, there were six laparotomy-confirmed complete responses (CRs) and three partial responses, for an overall response rate of 25.7% (nine of 35).",Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363872/),%,25.7,126548,DB00041,Aldesleukin
,9363872,survival time,The median survival time of the cohort was 13.7 months and the overall 5-year survival probability was 13.9%.,Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363872/),month,13.7,126549,DB00041,Aldesleukin
